Abt Holding Company

Augusta University Research Institute, Inc.

Other

Athersys, Inc.

Case Western Reserve University

Medical College of Georgia

Robert W Mays

Robert J Deans

Cesar V Borlongan

David C Hess

James E Carroll

John Joseph Harrington

Jerry Silver

Paul David Jackson

Anthony E Ting

Pieter W Faber

Benjamin Philip Faga

Gregory B Foust

Thomas H Gentry

George Mbella Ekema

Kevin P Horn

Sarah A Busch

Jason A Hamilton

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.

MAPC therapeutics without adjunctive immunosuppressive treatment

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

MAPC treatment of brain injuries and diseases

The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4and CD8T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1&#x3b2;, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.

Modulation of splenocytes in cell therapy

The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated conditions.

Calcium-sensing receptor 2 (CaR2) and methods for using

Roof replacement structure for flat roof building having panels of rigid insulation applied over the roof surface. A flexible membrane is applied over the rigid insulation and a periphery of the membrane overlapping a side of the building is fastened thereto with a termination bar.

Replacement flat roof insulation cover

Growing community of inventors

Shaker Heights, OH, United States of America

Robert W Mays